MARK KAEHR, MD
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician in CARMEL, Indiana. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
MARK KAEHR, MD reported a CMS MIPS final score of 100/100 — above the 83.1 national average — and filed 641 Medicare Part D claims in 2023.
- 100/100
- MIPS score · +17 vs avg
- 641
- Part D claims, 2023
- 65%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
MARK KAEHR, MD's MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
100 Top 7% higher than 93% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
MARK KAEHR, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about MARK KAEHR, MD?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Indiana
How Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician compares to other specialties among Indiana providers
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician share within Indiana
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician is one of the more visible NUCC categories in Indiana
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
MARK KAEHR, MD's 2023 MIPS final score plotted against the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician national average
- MIPS Final Score
- 100/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician) — 100/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Specialty volume Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician US NPIs
100/100 MIPS final score — 16.9 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician. Quality dim: 100.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
MARK KAEHR, MD appears in the CMS NPPES registry as a Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider holding MD credentials at 12794 HAMILTON CROSSING BLVD, CARMEL, IN, 46032, with a listed phone of (317) 571-1501. NPI 1427361450 was issued on 07/19/2010. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what KAEHR most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 641 prescription claims written by this provider, covering 192 Medicare beneficiaries and totaling roughly $486K in drug spend, split 35% brand-name and 65% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 100/100 for the 2023 performance year (Quality 100), compared with the national average of 83.1.
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician is a narrow specialty nationwide, with 37 enrolled providers across 15 states and an average of 642 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1427361450 |
|---|---|
| Specialty | Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician |
| Credentials | MD |
| Gender | Male |
| NPI Issued | 07/19/2010 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm MARK KAEHR, MD's current license status, disciplinary history, and board certifications with the Indiana Medical Licensing Board in Indiana before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Group practice
Hospital and facility affiliations
Facilities where MARK KAEHR, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Brand vs generic prescribing mix · Above average
35% brand-name claims vs 65% generic, on 641 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 1,037
- Total Day Supply
- 28,875
- Brand vs Generic
- 35% brand / 65% generic
- Brand Drug Cost
- $464K
- Generic Drug Cost
- $22K
Patient Demographics
- Average Patient Age
- 72.7 years
- Avg HCC Risk Score
- 1.65
- Gender Split
- 51% female / 49% male
- Age Distribution
- <65: 20, 65-74: 94, 75-84: 58, 85+: 20
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What MARK KAEHR, MD prescribes most
Top Medicare Part D drugs by claim count, 2023
- Prednisolone Acetate
Prednisolone Acetate
125 claims
- Dorzolamide-Timolol
Dorzolamide-Timolol
72 claims
- Difluprednate
Difluprednate
69 claims
- Moxifloxacin 37
Moxifloxacin
37 claims
- Prednisone 36
Prednisone
36 claims
- Humira(Cf) Pen 30
Humira(Cf) Pen
30 claims
- Ofloxacin 30
Ofloxacin
30 claims
- Ketorolac Trometha… 25
Ketorolac Tromethamine
25 claims
| Drug | Claims |
|---|---|
| Prednisolone Acetate | 125 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 72 |
| Difluprednate | 69 |
| Moxifloxacin Moxifloxacin Hcl | 37 |
| Prednisone | 36 |
| Humira(Cf) Pen Adalimumab | 30 |
| Ofloxacin | 30 |
| Ketorolac Tromethamine | 25 |
| Latanoprost | 23 |
| Brimonidine Tartrate | 19 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Overview
How MARK KAEHR, MD fits within the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician landscape nationally.
MARK KAEHR, MD's 641 claims are below the specialty average of 642.
Nearby Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Providers in Indiana
Other clinicians with the same primary specialty enrolled in Indiana, drawn from the same CMS NPPES roster as KAEHR.
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Indiana
Frequently Asked Questions
What is MARK KAEHR, MD's specialty? ▼
How much does MARK KAEHR, MD prescribe under Medicare Part D? ▼
What is MARK KAEHR, MD's Medicare quality score? ▼
Where is MARK KAEHR, MD located? ▼
What is MARK KAEHR, MD's NPI number? ▼
Does MARK KAEHR, MD prescribe more brand-name or generic drugs? ▼
How many Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers are there in the US? ▼
What drugs does MARK KAEHR, MD prescribe most often? ▼
Does MARK KAEHR, MD accept Medicare? ▼
How can I verify MARK KAEHR, MD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology